But with reams of data on the drugs' health benefits beyond reducing obesity—including mitigating heart disease, diabetes, chronic kidney disease, and sleep apnea—most seem to have finally accepted their potentially immense societal value.
Now comes the hard part. These highly effective drugs—GLP-1s—are changing the way obesity is viewed and treated. The changes are coming so fast and could benefit so many that they've created new questions and ethical quandaries for medical professionals, including who should get them.
The theoretical market for Wegovy and Zepbound is massive: The Food and Drug Administration approved them for anyone with a body-mass index of 30 or more—27 or higher for individuals with a weight-related condition like high blood pressure or sleep apnea. Some 57 million working-age Americans with private insurance match those criteria, as do nearly 14 million retirement-age Americans. The expectation is that once started, the drugs will need to be taken for life to maintain the results.
Esta historia es de la edición December 26, 2024 de Financial Express Delhi.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición December 26, 2024 de Financial Express Delhi.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor? Conectar
Walmart Asks China Suppliers For Price Cuts
WALMART HAS ASKED some Chinese suppliers for major price reductions, with the US retail giant's efforts to shift the burden of President Donald Trump's tariffs facing strong pushback from firms in the Asian nation, according to people familiar with the matter.
ECB cuts rates, keeps door ajar for more easing
The European Central Bank lowered interest rates for the sixth time since June and indicated that its cutting phase may be drawing to a close as inflation cools and the economy digests seismic shifts in geopolitics.
Insolvency board mulls more regulatory changes
Even as the amendments to the Insolvency and Bankruptcy Code (IBC) are getting delayed, the Insolvency and Bankruptcy Board of India (IBBI) is planning a slew of regulatory changes to enhance the efficiency of the resolution process.
Taxpayers Declare Foreign Assets Worth ₹29,000 Cr
Declarations Come After CBDT Rolled Out Awareness Campaign
Yield softens to one-month low on liquidity push
Boosting Sentiment
Boeing CEO Kelly Wants 'Brutal' Honesty From Workers
\"I want to hear what the employees have to say,\" Ortberg said during his second companywide address to Boeing workers on Wednesday. \"And what we'll do is we're going to put an action plan on those things, and I think they're going to be brutal to leadership, quite frankly.\"
US Trade Deficit Surges to Record in Jan
US weekly jobless claims drop
We do not need to raise CNG prices
Mahanagar Gas plans to spend ₹1,000 crore in FY26 as capex compared with ₹800 crore in the current financial year.
Rajneet Kohli resigns as Britannia CEO
BRITANNIA INDUSTRIES ON Thursday announced that its chief executive officer (CEO) Rajneet Singh Kohli has resigned and will be relieved from his role on March 14.
Birla Opus steps on the gas with discounts, offers
BIRLA OPUS, THE paints venture of the Aditya Birla group, is offering nearly double the amount of price-offs or discounts on products, at 6-7%, compared to rivals such as Asian Paints and Berger, whose price discounts are at about 3-4% on its products, trade and industry sources have told FE.
